Previous research in patients with non‐small cell lung cancer (NSCLC) showed a reduction in the EGFR mutation frequency after chemotherapy [31], but no reports have been published about the impact of targeted therapy or immune checkpoint inhibitors. This evidence concerns the gene EGFR and non-small cell lung carcinoma.